
WHAT IS CLAIMED IS

1. A compound of Formula (I'),



Formula (**I'**)

or a pharmaceutically acceptable salt, or a stereoisomeric or tautomeric form thereof, wherein:

Z is -O-;

Y is $-(CH_2)_3-NR_9R_{10}$;

R_1 is thiazolyl, isothiazolyl, or thiadiazolyl;

R_2 is independently at each occurrence -F, -Cl, or -CN;

R_3 is independently at each occurrence -H, -F, or -Cl;

R_9 is (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, pyrazolyl or pyridinyl; wherein R_9 is optionally further substituted with 1 or 2 substituents selected from the group consisting of -COOH, $-COOR_{11}$, $-CONR_{11}R_{12}$, $-SO_2R_{11}$, $-SO_2NR_{11}R_{12}$, -OH, -CN, $-OR_{11}$, and $-NR_{11}R_{12}$; wherein R_{11} and R_{12} may form a 6 membered heterocycloalkyl ring;

R_{10} is (C_3 -C_6)alkynyl, (C_3-C_6)alkenyl; or R_9 and R_{10} together form a unsubstituted 4- to 8-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is fused with a 5-membered heteroaryl; and

R_{11} and R_{12} are independently H or (C_1-C_6)alkyl, optionally substituted with 4- to 8-membered heterocycloalkyl ring; and

m and n are each independently 1, or 2.

2. The compound of claim 1, wherein R_2 is independently at each occurrence -F or -Cl.

3. The compound of claim 1, wherein n is 2.

4. The compound of claim 1, wherein R_3 is independently at each occurrence -F, or -Cl.

5. The compound of claim 1, wherein m is 1.

6. The compound of claim 1, wherein R_9 is (C_1-C_6) alkyl; wherein R_9 is optionally further substituted with 1 or 2 substituents selected from the group consisting of -COOH, -COOMe, -CONH2, and -NH2.

7. The compound of claim 1, wherein R_9 is (C_1-C_6) alkyl, wherein R_9 is further substituted with —CONR$_{11}$R$_{12}$, wherein R_{11} and R_{12} are independently H or (C_1-C_6) alkyl.

8. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, or tautomeric form thereof and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is suitable for topical, oral, subcutaneous, or intravenous administration.

10. Use of a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, or tautomeric form thereof in the manufacture of a medicament for treating pain in a subject, wherein the medicament is to be administered to the subject.

11. The use of claim 10, wherein the therapeutically effective amount is effective to alleviate pain in a subject, wherein the compound of claim 1 shows a reduction in pain response in the Formalin Assay in phase 1 or phase 2, or both, at a dose between 0.1 mg/kg and 1,000 mg/kg, at a dose between 0.5 mg/kg and 100 mg/kg, or at a dose between 1 mg/kg to 50 mg/kg.

12. The use of claim 10, wherein the pain is nociceptive pain, such as that resulting from physical trauma includes a cut or contusion of the skin; or a chemical or thermal burn, osteoarthritis, rheumatoid arthritis or tendonitis; myofascial pain; neuropathic pain, such as that associated with stroke, diabetic neuropathy, luetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, fibromyalgia, or painful neuropathy induced iatrogenically by drugs; or mixed pain includes pain with both nociceptive and neuropathic components; visceral pain; headache pain includes migraine headache pain; CRPS; CRPS type I; CRPS type II; RSD; reflex neurovascular dystrophy; reflex dystrophy; sympathetically maintained pain syndrome; causalgia; Sudeck atrophy of bone; algoneurodystrophy; shoulder hand syndrome; post-traumatic dystrophy; autonomic dysfunction; autoimmune-related pain; inflammation-related pain; cancer-related pain; phantom limb pain; chronic fatigue syndrome; post-operative pain; spinal cord injury pain; central post-stroke pain; radiculopathy; sensitivity to temperature, light touch or color change to the skin includes allodynia; pain from hyperthermic or hypothermic conditions; and other painful conditions includes diabetic neuropathy, luetic neuropathy, postherpetic neuralgia, trigeminal neuralgia; chronic pain; acute pain; pain from neuromas, pain or itch associated with channelopathies includes small fiber neuralgia, IEM or Raynodes; or itch from various origins includes allergic itch.

13. The use of claim 10, wherein the compound is a voltage-gated sodium channel inhibitor of NaV1.7.

14. Use of a therapeutically effective amount of a compound of any one of claims 1-7, or pharmaceutically acceptable salt, solvate or tautomeric form thereof in the manufacture of a medicament for treating prediabetes or diabetes in a subject, wherein the medicament is to be administered to the subject.

15. The use of claim 10, wherein the pain is neuropathic, nociceptive or inflammatory pain.

16. The compound of claim 1, wherein R_9 and R_{10} together form a unsubstituted 4- to 8-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is fused with a 5-membered heteroaryl.

17. The compound of claim 1, wherein R_{10} is (C_3-C_6)alkylnyl or (C_3-C_6) alkenyl.

18. The compound of claim 1, wherein R_9 is (C_1-C_3) alkyl, wherein R_9 is optionally further substituted with 1 or 2 substituents selected from the group consisting of -COOH, -COOMe, -CONH2, and -NH2.

19. The compound of claim 1, wherein R_9 is (C_1-C_3) alkyl, wherein R_9 is further substituted with –$CONR_{11}R_{12}$, wherein R_{11} and R_{12} are independently H or (C_1-C_6) alkyl.